We are an early-stage biotech company aiming to combat (emerging) viral infectious diseases with a high unmet medical need via protease inhibition. With our proprietary technology platform, we are actively developing novel antiviral drugs that inhibit proteases and block viral replication. We aim for easy-to-administer drugs able to treat in epidemic and pandemic situations.

Read More…